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parable studies were pooled to obtain summary measures of cost
and effect. Cost data were converted to US dollars and expressed
as year 2002 prices. RESULTS: In total, 53 studies were identi-
ﬁed and reviewed, of which 13 were analysed. Median survival
of BSC was estimated at 4.90 months (95% CI 4.46–5.35). The
12-month and 24-month survival proportions were 16% (95%
CI13–19) and 4% (95% CI 2–7) respectively. Survival was 
not affected by the stage at which BSC was given. Four papers 
from two countries were suitable for pooling total costs of BSC,
and resulted in an estimate of US $6519 (95% CI $5740–$7297)
per person. CONCLUSION: Absolute effects, as observed in
clinical trials, pooled with meta-analysis techniques can provide
key information for outcomes research, such as pharmacoeco-
nomic modeling studies. Here we provide pooled survival and
cost estimates for BSC. These can be used for economic evalua-
tions of recently developed drugs in stage IIIb and IV NSCLC
where an indirect comparison may need to be made with BSC.
Pooling cost data is problematic due to differing treatment pat-
terns and relative prices over years and across countries. Conse-
quently, caution should be taken when pooling costs and it is
advised to only pool costs if studies are comparable. Otherwise
ranges of costs as observed in the different studies should be
reported.
PCN43
MAPPING HEALTH-RELATED QUALITY OF LIFE (HRQOL)
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OBJECTIVES: Pharmacoeconomic studies for terminal cancer
require preference-based rather than disease-speciﬁc measures of
QoL. Mapping enables evaluators to elicit information about
societal preferences where only disease-speciﬁc QoL data are
available. METHODS: Responses to HRQoL questions from a
phase-2 trial of VELCADE for relapsed and refractory multiple
myeloma patients (n = 202 in SUMMIT1 trial), were used to
derive utility scores from the original scales used in SUMMIT
and those from a generic QoL tool (EQ-5D). Questions relevant
to the EQ-5D were identiﬁed (EORTC-QLQC30, EORTC-
MY24, FACT-Fatigue and FACT/GOG-Ntx) and ﬁve summary
measures of severity (corresponding to the ﬁve EQ-5D dimen-
sions) obtained. The summary measures were transformed into
the corresponding EQ-5D scale for each dimension. EQ-5D
utility scores were validated using the answers to questions on
“Overall QoL” and “Overall Health” from EORTC-QLQC30
(Questions 29 & 30). RESULTS: Utility scores appear similar
across patient groups as deﬁned by serological response to
VELCADE, for an overall utility score of 0.65. Utility mapping
is sensitive to differences in overall QoL and overall health. This
ﬁnding is robust to the passage of time for overall QoL differ-
ences, but derived utility scores decline as time passes for a given
overall level of health. The utility scores are robust to mapping
algorithms that use summary measures (i.e. mean/median) to
aggregate reported severity levels for relevant questions within
each EQ-5D dimension but change markedly if the worst
reported level of severity for each dimension is used instead.
CONCLUSIONS: A method for deriving utility scores from
reported HRQoL outcomes is proposed that yields results con-
sistent with previous reports for MM patients. Using mapping
algorithms to derive utility scores from generic instruments in
situations where information on societal preferences for QoL
outcomes is not available is a feasible and sensitive option for
providing valid estimates of patient well-being for terminal 
conditions.
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OBJECTIVES: To conduct a meta-analysis on the diagnostic
accuracy of ﬁve screening tests for colorectal cancer (CRC): 
fecal occult blood test (FOBT), double-contrast barium 
enema (DCBE), ﬂexible sigmoidoscopy (FSIG), conventional
colonoscopy (COL) and computed tomography colonoscopy
(CTCOL). METHODS: A literature search was carried out in
MEDLINE for each test. Articles were reviewed by two inde-
pendent reviewers. Inclusion criteria were: 1) RCTs or observa-
tional studies of CRC screening; 2) patients with low/average
risk of CRC; 3) complete data to calculate sensitivity and speci-
ﬁcity. Exclusion criteria were: 1) non-peer reviewed articles; 2)
articles whose primary aim was not to assess CRC screening; 3)
articles not in English/French; 4) articles published prior to 1975;
and 5) high risk screening populations. Weighted linear regres-
sion was used to identify signiﬁcant covariates. Sensitivity and
speciﬁcity were pooled for relevant subgroups. RESULTS: The
initial literature search found 399 articles for FOBT, 253 for
DCBE, 394 for FSIG, 434 for COL, and 345 for CTCOL. Of
these, 12, 8, 10, 8, and 13 articles respectively, were included in
the ﬁnal analysis. With the exception of colonoscopy the remain-
ing tests showed evidence of heterogeneity and threshold effect.
Signiﬁcant covariates included study design and type of FOBT.
Pooled sensitivity and speciﬁcity (95% CI) for randomized FOBT
and FSIG trials were 0.738 (0.705,0.768), 0.960 (0.959,0.961),
0.822 (0.770,0.864), and 0.997 (0.994,0.998) respectively. For
the remaining tests, the pooled sensitivity and speciﬁcity (95%
CI) were 0.767 (0.728,0.802), 0.975 (0.970,0.979) for all DCBE
studies, 0.867 (0.828,0.898), 0.995 (0.991,0.998) for all COL
studies and 0.879 (0.840,0.910), 0.964 (0.956,0.971) for all
CTCOL studies. CONCLUSIONS: When heterogeneity is
present within test groups, results from pooled sensitivity and
speciﬁcity can be misleading. A planned future step is to estimate
diagnostic odds ratios and build summary ROC curves which
are more reliable estimates of test accuracy for evidence 
synthesis.
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OBJECTIVE: The aim of the project is to use Artiﬁcial Neural
Networks (ANNs)—representatives of computational intelli-
gence—for medical effect prediction, which could help in 
the extrapolation of pharmacoeconomics analysis’ results.
METHODS: To depict neural data analysis tools, a database
containing 100 non-small cell lung cancer (NSCLC) patients in
non-operative IIIB and IV stage has been used. Each patient was
described using 30 factors (i.e. sex, age, anticancer drugs dosage)
and, as an output value, the expected survival time was estab-
lished. The role of the ANN based system was to predict the
patient’s survival time based on the above mentioned informa-
tion. Binary values were tested as outcomes. Positive values
(coded as 1) meant that patient survival time would be equal to
or longer than 35 weeks. Negative values (coded as 0) meant
that the patient survival time would be shorter than 35 weeks.
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Binary values were obtained using a threshold, which based on
the mean survival time of patients derived from literature.
RESULTS: Back-propagation as well as fuzzy-logic neural net-
works were applied. A 10-fold cross validation method was used
to obtain the appropriate models. Final results were compared
with the generic, logistic regression-based model. The best pre-
diction score of the ANN model was 82% (generalization) and
was higher than logistic regression prediction rate. Best obtained
model was tested under its practical application in the in-silico
study to model switching from cisplatin to carboplatin therapy
in NSCLC. The results demonstrate that thanks to the better sur-
vival rate such operations could be cost-effective. CONCLU-
SIONS: Artiﬁcial Neural Networks could be applied in
pharmacoeconomics analysis as additional modeling tools.
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OBJECTIVES: To analyze the risk of re-hospitalization for
COPD following different treatment regimens. METHODS: A
retrospective cohort study with data from the Dutch PHARMO
system, including medication and hospital admission records of
1.6 million inhabitants of 34 Dutch cities was performed.
Patients >40yrs with a ﬁrst admission for COPD during
1992–2002 were identiﬁed. Treatment was assessed in the period
of 90 days following ﬁrst discharge. Cox proportional hazard
analysis was performed to analyze the time to re-hospitalization
for COPD for different treatment regimes. Hazard rate (HR) and
95% conﬁdence intervals (CI) were adjusted for potential risk
factors including gender, age, year of hospitalization and disease
severity. The maximum follow-up time was two years.
RESULTS: From the total cohort of 3855 patients, 1118 (29%)
were re-hospitalized within two years after the ﬁrst hospitaliza-
tion. The mean period to re-hospitalization was 230 days. Com-
pared to ICS as a reference group, an increased risk for
re-hospitalization was found in the following treatment groups:
theophylline (HR 1.83, CI 1.12–2.99), and ICS combined with
anticholinergics and beta-agonists (HR 1.50, CI 1.02–2.20).
CONCLUSIONS: This study found re-hospitalizations occurred
in approximately one-third (1/3) of patients. Differences in
COPD re-hospitalization risks between treatment groups were
observed. Anti-inﬂammatory therapy alone demonstrated a sig-
niﬁcant protective effect compared to theophylline therapy alone
or a combination therapy of ICS, anticholinergics and beta-
agonists.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
(COPD)—Methods and Concepts
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ITEM SELECTION FOR COPD-SPECIFIC UTILITY
INSTRUMENT
Meguro M, Jones PW
St George’s Hospital Medical School, London, UK
OBJECTIVE: To identify items in the existing disease-speciﬁc St.
George’s Respiratory Questionnaire (SGRQ) that might be suit-
able for use in a COPD speciﬁc utility instrument. METHOD:
The SGRQ has three domains. We planned to use three items per
domain (mild, moderate and severe) for the new instrument.
Using data from 893 patients we ﬁrst reduced the original 50
SGRQ items to the 40 “best” items using classical test methods
and Rasch modelling (RUMM 2010 software). The Person Sep-
aration Index for these 40 items was 0.9 (an “excellent” ﬁt to a
unidimensional model). We then used Rasch location maps to
identify suitable items. We examined those items that covered
95% of the patients, then divided the population into tertiles
according to their person location value: mild (mean location 
-0.97 logits, SD = 0.35), moderate (mean location 0.09 logits,
SD = 0.39), severe (mean location 1.45 logits, SD = 0.56). For
each level of patient severity we chose one item per SGRQ
domain using criteria based upon quality of ﬁt of the item to the
unidimensional model of all 40 items. RESULTS: We were able
to identify one suitable item per domain at each severity level.
The locations of the nine items ranged from -1.16 logits to 1.47
logits. The mean item location for the three mild items was 
-0.55 logits, moderate items 0.18 logits, severe items 1.16 logits.
CONCLUSION: We have now identiﬁed nine items from three
domains of health in COPD. Each item has a clearly deﬁned level
of severity. This approach should ensure that the utility instru-
ment, when fully developed, has good discriminative properties
and may also have good evaluative properties.
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OBJECTIVES: The purpose of this study is to establish a
measure of the COPD severity using claims data. METHODS:
The study sample was identiﬁed from a large claims database
covering the period 1999–2002. Patients of age 18–65 with pre-
vious acute exacerbation of COPD (AECB) were included in 
the study sample (n = 2068). Variables associated with COPD
severity were extracted. Variables with low face validity, high
endorsement rate (>97%), or low homogeneity (measured by
Chronbach’s alpha) were excluded. Principal component analy-
sis with orthogonal solution was conducted to identify the latent
severity score. Scree test and eigenvalue-one criterion were used
to determine the number of latent factors. The severity score was
standardized (mean = 50, SD = 10). Construct validity was tested
by comparing severe COPD patients to moderate/mild patients
of 3-month AECB incidence rate and by comparing the failure
rate (ER/hospitalization) of antibiotic treatment in AECB.
RESULTS: Six variables were excluded from the original 18
potential variables due to low face validity or high endorsement
rate. Principal component analysis based on the remaining 12
variables produced a single latent factor (eigenvalue = 3.6), there-
fore no factor rotation was performed. The score loaded high on
the use of oxygen therapy, corticosteroids, and bronchodilators,
etc. The resulting factor loading agreed with the clinical recom-
mendation in GOLD criteria of treating COPD by severity.
Chronbach’s alpha test showed good homogeneity of the sever-
ity score (0.71) and no input variables were rejected. The con-
struct validity tests showed that, compared with mild/moderate
COPD patients, severe patients were about 3 times more likely
to have AECB episodes and 60% more likely to have antibiotic
treatment failure in AECB episodes. CONCLUSIONS: The
COPD severity score developed in this study can be applied to a
wide range of retrospective studies of COPD, where results from
